Skip to content

Clinical trials

Phase 1/2 Squamous Cell Carcinoma of Head and Neck trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Squamous Cell Carcinoma of Head and Neck Phase: Phase 1/2 Country / region: United States Clear all

154 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20012
20022
20032
20041
20051
20061
20071
20081
20091
20105
20114
20123
20132
20141
20156
20163
20179
201815
201916
202012
202112
20228
202311
20249
202510
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed53
Recruiting39
Terminated32
Active, not recruiting20
Unknown status5
Not yet recruiting3
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)9
Washington University School of Medicine4
Incyte Biosciences International Sàrl3
University of Washington3
Alentis Therapeutics AG2
Amgen2
Daiichi Sankyo2
Dana-Farber Cancer Institute2
DualityBio Inc.2
Genmab2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Squamous Cell Carcinoma of Head and Neck154
Carcinoma, Non-Small-Cell Lung57
Head and Neck Neoplasms45
Melanoma38
Triple Negative Breast Neoplasms28
Colorectal Neoplasms25
Carcinoma, Renal Cell24
Uterine Cervical Neoplasms23
Ovarian Neoplasms21
Neoplasm Metastasis20

Trials

Showing 1 to 25 of 154. Each trial links to its page on Pharma Observatory.

54 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.